Skip to main content
All lobbying filings

PFIZER INC.

Lobbying for PFIZER INC.

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $1,720,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 6
 Lobbying activity 3
Health Issues

Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies

Medicare/Medicaid

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid

Trade (domestic/foreign)

International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem